Precision BioSciences Announces Two Oral Presentations Highlighting Updated Interim Data from Lead PBCAR0191 CAR T Immunotherapy for Relapsed and Refractory B-cell Malignancies at the 63rd Annual Meeting of the American Society of Hematology
- Enhanced Lymphodepletion Improved Overall Response Rate and Complete Response Rate Compared to Standard Lymphodepletion in Heavily Pretreated NHL and B-ALL Subjects with a Median of ~6 Prior Lines…
Precision BioSciences to Report Third Quarter 2021 Financial Results on November 10, 2021 and Participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 3, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T…
Precision BioSciences to Present at the Jefferies Virtual Gene Therapy/Editing Summit on Wednesday, October 27, 2021
DURHAM, N.C. --(BUSINESS WIRE)--Oct. 21, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS ® genome editing platform to develop allogeneic CAR…
Precision BioSciences Statement on Safety of its Allogeneic CAR T Cells
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, issued the…
Precision BioSciences Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 27, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T…
Precision BioSciences Appoints Michael Amoroso Chief Executive Officer
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 27, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS genome editing platform to develop allogeneic CAR T…
Precision BioSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 10, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies…
Precision BioSciences Outlines Clinical Development Strategy for In Vivo Gene Editing Pipeline
- Accelerated Clinical Development Expected to Enable Three Investigational New Drug/Clinical Trial Applications Within Next Three Years, Including for Familial Hypercholesterolemia as early as 2022,…
Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing Therapies
iECURE to License Precision’s PCSK9-Directed ARCUS Nuclease and Pursue Four Gene Insertion Programs Focused on Liver Diseases; Precision Retains Rights Across All Indications Except Those Licensed to…
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
Precision Gains Access to Tiziana’s Anti-CD3 Antibody, Foralumab, to Evaluate as a Lymphodepletion Agent with its Allogeneic CAR T Portfolio DURHAM, N.C. , NEW YORK & LONDON --(BUSINESS…